Avid Bioservices Inc (CDMO)

[Protector]

entdoc, that question is answered in PPHM's PR:

For instance, what percentage of patients showed the improvement? How much improvement?

The answer is : a sufficient large sample of BOTH arms in order to be able to come to the conclusion that there is statistical relevance.

So it is impossible that we are talking about 10 or 20 patients given the scale of the clinical trial in which it was observed.

And believe me, in Lung Cancer an over-all survival of end-points that have been designed for the drug to become SOC (Standard of Care) is commercially marketable.

In other words, OS might be extended from 6 months to 8 months, which might attain statistical significance, but is not a marketable difference in treatment.

Look at Opdivo alone, as you will see it performed LESS GOOD then bavituxmab+docetaxel and yet at 150K$ per full treatment people go for this drug that delays their death (yet will come back within a window of abou 12 to 36 months.

With bavituximab you have an immune response.